Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
NU E Power Corp. Announces Closing of Non-Brokered Private Placement for $1.7 Million. (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Enliven Therapeutics Inc ELVN

Healthcare Biotechnology
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a CNS penetrant and irreversible HER2... see more

Current News (NDAQ:ELVN)

Enliven Therapeutics Reports Inducement Grants as Permitted by the Nasdaq Listing Rules

PR Newswire December 11, 2025

Enliven Therapeutics Announces New CEO to Drive Next Phase of Development

PR Newswire December 11, 2025

Enliven Therapeutics Reports Third Quarter Financial Results and Provides a Business Update

PR Newswire November 12, 2025

Enliven Therapeutics Announces Oral and Poster Presentations at the Society of Hematologic Oncology (SOHO) 2025 Annual Meeting

PR Newswire August 25, 2025

Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update

PR Newswire August 13, 2025

Enliven Therapeutics Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares

PR Newswire June 16, 2025

Enliven Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

PR Newswire June 13, 2025

Enliven Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

PR Newswire June 13, 2025

Enliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML at EHA 2025 Congress

PR Newswire June 13, 2025
View More News ››

Opinion & Analysis (NDAQ:ELVN)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:ELVN)

Enliven Therapeutics, Inc. (ELVN): A Promising Precision Onc

http://beyondspx.com/2024/07/31/enliven-therapeutics-inc-elvn-a-promising-precision-oncology-player-poised-for-growth/
MikeTester - August 2, 2024
View more Bullboard ››

TAG Oil Ltd.

TAG Oil Ltd.

TAG Oil Ltd., together with its subsidiaries, engages in the exploration, development, and production of oil and gas in ...
View More »

Podcasts